Company Overview and News
• The propylene glycol market projected to grow at a CAGR of 5.8% during the forecast period
The report "Propylene Glycol Market by Source (Petroleum and Bio-Based), Application (Unsaturated Polyester Resin, Antifreeze & Functional Fluid, Food, Pharmaceuticals & Cosmetics), End-Use Industry (Transportation, Building & Construction) - Global Forecast to 2021", published by MarketsandMarkets™, the global market was valued at USD 3.47 Billion in 2016, and is projected to grow at a CAGR of 5.8% from 2016 to 2021, to reach USD 4.
NEW YORK, Feb. 22, 2017 /PRNewswire/ -- "Modified starch market is projected to grow at a CAGR of 4.1%"
LONDON, June 16, 2016 /PRNewswire/ -- The global modified starch market is expected to reach USD 15.36 billion by 2024, according to a new report by Grand View Research, Inc. Growing demand for modified starch as a stabilizer, thickening agent, binder, and emulsifier in food & beverage, paper, and textile applications will augment growth. Competitive pricing owing to a large number of suppliers is expected to be a key feature of the industry over the next seven years.
BEIJING, April 1 China's plan to let the market set corn prices is bad news for international grain exporters, but should boost the country's struggling corn processors that use the grain in products ranging from food additives to paper and textiles.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...